Spotlight on Bupropion in Major Depressive Disorder

被引：0
|
作者：
Sohita Dhillon
Lily P. H. Yang
Monique P. Curran
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
CNS Drugs | 2008年 / 22卷
关键词：
Major Depressive Disorder; Sustained Release; Bupropion; Major Depressive Disorder; Escitalopram;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Bupropion is presumed to be a dopamine-noradrenaline (norepinephrine) reuptake inhibitor and is an effective antidepressant. It is available as three oral formulations: (i) bupropion immediate release (IR) [Wellbutrin®] administered three times daily; (ii) bupropion sustained release (SR) [Wellbutrin SR®] administered twice daily; and (iii) bupropion extended/modified release (XR) [Wellbutrin XL®/Wellbutrin XR®] administered once daily. All three formulations are bioequivalent in terms of systemic exposure to bupropion.
引用
收藏
页码：613 / 617
页数：4
相关论文
共 50 条
  • [1] Spotlight on Bupropion in major depressive disorder
    Dhillon, Sohita
    Yang, Lily P. H.
    Curran, Monique P.
    [J]. CNS DRUGS, 2008, 22 (07) : 613 - 617
  • [2] Spotlight on escitalopram in the management of major depressive disorder
    Murdoch, D
    Keam, SJ
    [J]. CNS DRUGS, 2006, 20 (02) : 167 - 170
  • [3] Spotlight on Escitalopram in the Management of Major Depressive Disorder
    David Murdoch
    Susan J. Keam
    [J]. CNS Drugs, 2006, 20 : 167 - 170
  • [4] The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder
    Ricardo Moreira
    [J]. Clinical Drug Investigation, 2011, 31 : 5 - 17
  • [5] The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder
    Moreira, Ricardo
    [J]. CLINICAL DRUG INVESTIGATION, 2011, 31 : 5 - 17
  • [6] Bupropion in the treatment of major depressive disorder: a comparison with paroxetine
    Calandra, C.
    Terranova, F.
    Loiacono, P.
    Caudullo, V.
    Russo, R. G.
    Luca, M.
    Cafiso, M.
    [J]. JOURNAL OF PSYCHOPATHOLOGY, 2010, 16 (01): : 128 - 133
  • [7] Bupropion in the treatment of outpatients with asthma and major depressive disorder
    Brown, E. Sherwood
    Vornik, Lana A.
    Khan, David A.
    Rush, A. John
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, 2007, 37 (01): : 23 - 28
  • [8] Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
    Jefferson, JW
    Pradko, JF
    Muir, KT
    [J]. CLINICAL THERAPEUTICS, 2005, 27 (11) : 1685 - 1695
  • [9] Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder
    Willett, Kristine C.
    Bond, LeDea R.
    Morrill, Amanda M.
    Lorena, Dima
    Petru, Ifteni
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (01) : e24 - e29
  • [10] Dextromethorphan/bupropion in major depressive disorder: a profile of its use
    Blair, Hannah A.
    [J]. DRUGS & THERAPY PERSPECTIVES, 2023, 39 (08) : 270 - 278
12345